- Home
- KYMR vs DYN Comparison
KYMR vs DYN Comparison
Compare KYMR & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KYMR
- DYN
- Stock Information
- Founded
- KYMR 2015
- DYN 1984
- Country
- KYMR United States
- DYN United States
- Employees
- KYMR N/A
- DYN N/A
- Industry
- KYMR Medicinal Chemicals and Botanical Products
- DYN Medicinal Chemicals and Botanical Products
- Sector
- KYMR Health Care
- DYN Health Care
- Exchange
- KYMR Nasdaq
- DYN Nasdaq
- Market Cap
- KYMR 1.8B
- DYN 1.4B
- IPO Year
- KYMR 2020
- DYN 2020
- Fundamental
- Price
- KYMR $45.87
- DYN $10.32
- Analyst Decision
- KYMR Strong Buy
- DYN Strong Buy
- Analyst Count
- KYMR 16
- DYN 14
- Target Price
- KYMR $59.38
- DYN $44.57
- AVG Volume (30 Days)
- KYMR 1.1M
- DYN 2.5M
- Earning Date
- KYMR 08-06-2025
- DYN 08-11-2025
- Dividend Yield
- KYMR N/A
- DYN N/A
- EPS Growth
- KYMR N/A
- DYN N/A
- EPS
- KYMR N/A
- DYN N/A
- Revenue
- KYMR $58,885,000.00
- DYN N/A
- Revenue This Year
- KYMR $43.38
- DYN N/A
- Revenue Next Year
- KYMR $10.97
- DYN N/A
- P/E Ratio
- KYMR N/A
- DYN N/A
- Revenue Growth
- KYMR N/A
- DYN N/A
- 52 Week Low
- KYMR $19.45
- DYN $6.36
- 52 Week High
- KYMR $53.27
- DYN $47.45
- Technical
- Relative Strength Index (RSI)
- KYMR 67.58
- DYN 34.25
- Support Level
- KYMR $45.80
- DYN $10.56
- Resistance Level
- KYMR $47.51
- DYN $15.23
- Average True Range (ATR)
- KYMR 2.86
- DYN 1.01
- MACD
- KYMR -0.03
- DYN -0.47
- Stochastic Oscillator
- KYMR 67.19
- DYN 4.10
About KYMR Kymera Therapeutics Inc.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.